The Readout Loud 388: The FDA's refusal to review Moderna's mRNA flu vaccine
10 snips
Feb 12, 2026 Jesse Goodman, former FDA official with deep regulatory experience, offers perspective on refuse-to-file norms. Lizzy Lawrence, STAT reporter, brings inside reporting on FDA vaccine office dynamics. Stephen Hoge, Moderna president, explains the company’s mRNA flu strategy and regulatory interactions. They discuss the FDA blocking review, trial design disagreements, comparators, and how agency decisions affect innovation and global strategy.
AI Snips
Chapters
Transcript
Episode notes
Unusual Refusal Over Trial Comparator
- The FDA's refusal to review Moderna's mRNA flu vaccine hinged on its choice of comparator in the Phase III trial.
- Vinay Prasad said the trial was not "adequate and well-controlled," creating an unusual rejection despite prior agency acceptance.
Moderna Says FDA Approved The Protocol
- Stephen Hoge said Moderna sought and received written pre-phase III agreement from the FDA that their trial design was acceptable.
- Moderna submitted the protocol, ran the 41,000-person trial, and had no clinical hold or major protocol objections from the agency.
Refuse-To-File Is A High Bar
- Refuse-to-file letters are rare and usually signal missing data or major defects, not disagreements over comparators.
- Moderna views the agency's change as moving the goalposts after a billion-dollar trial and prior acceptance.